|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
IRCT |
|
Last refreshed on:
|
22 February 2018 |
|
Main ID: |
IRCT2014052617851N1 |
|
Date of registration:
|
2016-12-02 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Cellobiose Effect On the Intestinal Glucose Absorption
|
|
Scientific title:
|
The Effect Of Cellobiose In the Reduction Of Intestinal Glucose Absorption In Patients With Impaired Glucose Tolerance |
|
Date of first enrolment:
|
2016-12-01 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Complete |
|
URL:
|
http://en.irct.ir/trial/16327 |
|
Study type:
|
interventional |
|
Study design:
|
Randomization: N/A, Blinding: Single blinded, Placebo: Not used, Assignment: Single, Purpose: Diagnostic.
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Iran (Islamic Republic of)
| | | | | | | |
|
Contacts
|
|
Name:
|
Laleh Mahmoudi
|
|
Address:
|
school of pharmacy, shiraz university of medical sciences
Shiraz
Iran (Islamic Republic of) |
|
Telephone:
|
+98 71 3242 4128 |
|
Email:
|
mahmoudi_l@sums.ac.ir |
|
Affiliation:
|
Shiraz University of Medical Science, School of Pharmacy |
|
|
Name:
|
Hamed Maleknasab
|
|
Address:
|
No.# 501, Sahba Building, Ghodousi sharghi Blvd.
7184994539
Shiraz
Iran (Islamic Republic of) |
|
Telephone:
|
+98 71 3843 6769 |
|
Email:
|
maleknasab@sums.ac.ir mahmoudi_l@sums.ac.ir |
|
Affiliation:
|
Shiraz University of Medical Science, School of Pharmacy |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Inclusion Criteria: Patients in pre-diabetes stage or impaired glucose tolerance via convenience method are included.
Exclusion Criteria : Age >60 or age <18 ; Overt diabetes (type 1/ type 2) ; Consumption of any anti diabetic drug ; Poor cooperation ; Malignancy ; Pregnancy and lactation ; Chronic liver diseases.
Exclusion criteria:
Age minimum:
18 years
Age maximum:
59 years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
pre-diabetes.
Abnormal glucose tolerance test
|
|
Abnormal glucose tolerance test
|
|
Intervention(s)
|
|
Diagnosis
|
Intervention 1: Control group:
In this step volunteers do oral glucose tolerance test according to American Diabetes Association's(ADA) instruction. Intervention 2: Intervention group:
In this step volunteers take 30g cellobiose during oral glucose tolerance test in addition to glucose administration, simultaneously.
|
|
Treatment - Drugs
|
Control group:
In this step volunteers do oral glucose tolerance test according to American Diabetes Association's(ADA) instruction.
|
Intervention group:
In this step volunteers take 30g cellobiose during oral glucose tolerance test in addition to glucose administration, simultaneously.
|
|
Primary Outcome(s)
|
|
Blood glucose level. Timepoint: At time 0 and then 1 and 2 and 3 hours after oral glucose tolerance test. Method of measurement: variable unit of measurement:mg/dl method of measuring: Venesection.
|
|
Source(s) of Monetary Support
|
|
Shiraz University of Medical Sciences
|
|
Ethics review
|
Status: Approved
Approval date:
Contact:
Ethics Committee of Shiraz University of Medical Science
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|